Patent Eligibility of Medical Diagnostic Methods : vimarsana

In CareDx, Inc. v. Natera, Inc., Court of Appeals for the Federal Circuit held CareDx’s patent claims to methods of detecting organ transplant rejection were invalid as patent ineligible under 35 U.S.C. section 101. Claims to medical diagnostics face unique challenges.

Related Keywords

, Natera Inc , Us Court , Power Grp , Bank Intl , District Court Granted Summary Judgment , Eurofins Viracor Inc , Mayo Collaborative Servs , Prometheus Laboratories Inc , True Health Diagnostics , Mayo Collaborative Services , Ariosa Diagnostics Inc , Supreme Court , Illumina Inc , Caredx Inc , Alice Corp , Athena Diagnostics Inc , Federal Circuit , Invasive Diagnosis , Graft Rejection , Organ Transplant , Eurofins Viracor , Mayo Step , Athena Diagnostics , Collaborative Servs , Cleveland Clinic , Health Diagnostics , Legal , Business , Government , Caredxv Natera , Edical Diagnostic Method , Intellectual Property , Iagnostic Patent , 5u Sc Section 101 , Lice Corpv Cls Bank , Mayo Collaborative Servicesv Prometheus Laboratories ,